MarketsPiramal Pharma Limited PPLPHARMA
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 17,965.04 | 15,677.59 | 15,311.81 |
| Accumulated Depreciation Total | -3,519.66 | -2,809.2 | -2,363.59 |
| Cash Equivalents | 225.03 | Not available | Not available |
| Other Liabilities Total | 250.56 | 224.27 | 200.22 |
| Accrued Expenses | 130.86 | 210.15 | 159.43 |
| Long Term Debt | 4,299.97 | 3,214.07 | 2,483.75 |
| Common Stock Total | 1,327.16 | 1,324.35 | 1,322.95 |
| Other Equity Total | 892.56 | 544.73 | 458.68 |
| Other Current Assets Total | 31.7 | 157.42 | 140.5 |
| Prepaid Expenses | 97.74 | 79.18 | 64.02 |
| Total Assets | 17,965.04 | 15,677.59 | 15,311.81 |
| Current Portof LT Debt/Capital Leases | 491.39 | 547.92 | 937.04 |
| Additional Paid-In Capital | 4,768.3 | 4,737.2 | 4,724.94 |
| Cash | 974.85 | 368.98 | 356.82 |
| Total Equity | 8,162.62 | 8,125.47 | 7,911.37 |
| Long Term Investments | 305 | 271.09 | 240.26 |
| Retained Earnings(Accumulated Deficit) | 1,174.6 | 1,519.19 | 1,404.8 |
| Total Common Shares Outstanding | 132.72 | 132.44 | 132.29 |
| Property/Plant/Equipment Total-Gross | 9,161.52 | 7,832.69 | 7,179.55 |
| Tangible Book Valueper Share Common Eq | 30.3 | 30.5 | 27.38 |
| Goodwill Net | 1,257.43 | 1,148.21 | 1,122.55 |
| Total Liabilities | 9,802.42 | 7,552.12 | 7,400.44 |
| Total Debt | 5,674.59 | 4,856.47 | 4,710.16 |
| Short Term Investments | 131.78 | 19.56 | 144.69 |
| Cashand Short Term Investments | 1,331.66 | 388.54 | 501.51 |
| Total Receivables Net | 2,478.98 | 2,718.35 | 2,462.03 |
| Notes Payable/Short Term Debt | 747.8 | 995.32 | 1,171.38 |
| Deferred Income Tax | 358.18 | 248.35 | 229.18 |
| Accounts Receivable-Trade Net | 2,212.03 | 2,376.84 | 2,135.56 |
| Property/Plant/Equipment Total-Net | 5,641.85 | 5,023.49 | 4,815.97 |
| Total Current Liabilities | 4,758.28 | 3,766.27 | 4,369.3 |
| Total Inventory | 3,251.58 | 2,453.5 | 2,296.41 |
| Accounts Payable | 2,479.11 | 1,533.77 | 1,538.37 |
| Other Currentliabilities Total | 909.12 | 479.11 | 563.08 |
| Total Long Term Debt | 4,435.4 | 3,313.23 | 2,601.74 |
| Intangibles Net | 2,884.47 | 2,938.63 | 3,167.21 |
| Other Long Term Assets Total | 552.21 | 413.83 | 407.33 |
| Note Receivable-Long Term | 132.42 | 85.35 | 94.02 |
| Total Current Assets | 7,191.66 | 5,796.99 | 5,464.47 |
| Capital Lease Obligations | 135.43 | 99.16 | 117.99 |
Valuation and ratios
Growth
Debt 5Yr CAGR %100.7
Margins
Operating Margin 12m-1.19
Operating Margin 5y Avg11.74
Net Profit Margin 12m-3.68
Net Profit Margin 5y-0.07
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio0.27
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk37.97
Recommendations
RatingStrong Buy
Target High215
Target Low132.5
Target Mean1.44
Target Median55.56
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Sun Pharmaceutical Industries | INR 1,937.45 | 4.65 L | 38.4 | — |
| — | Divi's Laboratories | INR 7,371.1 | 1.96 L | 73.32 | — |
| — | Torrent Pharmaceuticals | INR 4,981.75 | 1.69 L | 72.73 | — |
| — | Cipla | INR 1,410.35 | 1.14 L | 27.57 | — |
| — | Zydus Lifesciences | INR 1,120.85 | 1.12 L | 21.19 | — |
Ownership
- Promoter
- 34.80%
- FII
- 12.51%
- MF
- 13.18%
- Other
- 39.51%
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- dividendRs.0.1400 per share(1.4%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.0.1100 per share(1.1%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- rightsRights issue of equity shares of Rs. 10/- in the ratio of 5:46 @ premium of Rs. 71/-.
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Indian stock indices faced losses on 20 July as HDFC Bank's disappointing earnings pressured the market. The BSE Sensex dropped 0.72%. Additionally, rising crude oil prices due to escalating Middle East tensions contributed to negative investor sentiment across sectors.
Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.
The Indian stock market extended its losses on March 12, with the Nifty 50 and Sensex down 1% and 1.08%. Tensions in the Middle East affected investor sentiment, particularly impacting auto stocks, while broader markets showed some positive movement.
Buy or sell stocks: Vaishali Parekh recommends three stocks to buy today — Piramal Pharma, Bharat Dynamics, and Oberoi Realty
Piramal Pharma's plea is slated to be heard on 9 February before a bench led by Chief Justice of India Surya Kant, along with Justices Joymalya Bagchi and N.V. Anjaria.
The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹ 2,140 crore, and slipping to a loss of ₹ 136 crore from a net profit of ₹ 4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.
Stocks to Watch: Tata Power received a letter for Jejuri Hinjewadi Power Transmission project. Infosys completed a buyback and saw stake reductions by co-founders' kin. Adani Power is pursuing South Asian projects. Piramal Pharma addressed FDA issues, while Firstsource acquired Pastdue Credit.
Ganesh Dongre of Anand Rathi recommends three stocks to buy on Monday - Indian Energy Exchange, Piramal Pharma Ltd, and Bajaj Finance.
Business information
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- PPLPHARMA
- BSE Code
- 543635
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Piramal Pharma?
Piramal Pharma has the symbol PPLPHARMA and ISIN - INE0DK501011.
What is the current price of Piramal Pharma?
Piramal Pharma is currently trading at INR 178.48.
What are the year high and year low of Piramal Pharma?
Piramal Pharma has a year high of INR 215.00 and a year low of INR 132.50.
What is the market capitalization of Piramal Pharma?
Piramal Pharma has a market capitalization of INR 23,614.20 crore.
What is the P/E ratio of Piramal Pharma?
Piramal Pharma has a P/E ratio of NA.
What is the dividend yield of Piramal Pharma?
Piramal Pharma has a dividend yield of 0.00%.
How is the financial performance of Piramal Pharma based on revenue, net income, and EPS?
Piramal Pharma has revenue of INR 88,690.80 crore, net income of INR -3,259.40 crore, and EPS of INR -1.50.
What is the book value of Piramal Pharma?
Piramal Pharma has a book value of INR 30.30.
What is the debt-to-equity ratio of Piramal Pharma?
Piramal Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Piramal Pharma?
Piramal Pharma has a price-to-book ratio of 5.89 and a price-to-sales ratio of 0.27.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
